Chloroquine
Aralen, Chloroquine (chloroquine) is a small molecule pharmaceutical. Chloroquine was first approved as Aralen hydrochloride on 1982-01-01. It is used to treat amebiasis, avian malaria, discoid lupus erythematosus, falciparum malaria, and malaria amongst others in the USA. It is known to target mas-related G-protein coupled receptor member X1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Chloroquine hydrochloride
Chloroquine phosphate
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| chloroquine phosphate | ANDA | 2024-01-09 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J0390 | Injection, chloroquine hydrochloride, up to 250 mg |
Clinical
Clinical Trials
245 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Malaria | D008288 | EFO_0001068 | B54 | 14 | 6 | 20 | 14 | 18 | 70 |
| Covid-19 | D000086382 | — | U07.1 | 2 | 18 | 18 | 9 | 9 | 48 |
| Vivax malaria | D016780 | EFO_0007445 | B51 | 1 | 8 | 10 | 13 | 6 | 36 |
| Falciparum malaria | D016778 | EFO_0007444 | B50 | 5 | 9 | 8 | 8 | 7 | 31 |
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | — | — | 8 | 2 | 1 | 11 |
| Coronavirus infections | D018352 | EFO_0007224 | B34.2 | — | 2 | 2 | 1 | 2 | 6 |
| Anemia | D000740 | HP_0001903 | D64.9 | — | — | 2 | 1 | 2 | 5 |
| Sars-cov-2 | D000086402 | — | — | — | 1 | 1 | 1 | — | 3 |
| Asymptomatic diseases | D058070 | — | — | — | — | 1 | 1 | — | 2 |
| Glucosephosphate dehydrogenase deficiency | D005955 | EFO_0007287 | — | — | 1 | — | 1 | — | 2 |
Show 6 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Glioblastoma | D005909 | EFO_0000515 | — | 3 | 2 | 1 | — | — | 5 |
| Hiv infections | D015658 | EFO_0000764 | B20 | — | 3 | 1 | — | 1 | 4 |
| Coronavirus | D017934 | — | — | — | — | 1 | — | 2 | 3 |
| Hiv | D006678 | — | O98.7 | — | — | 1 | — | 2 | 3 |
| Sickle cell anemia | D000755 | EFO_0000697 | D57 | — | 1 | 2 | — | — | 2 |
| Sexually transmitted diseases | D012749 | — | A50-A64 | — | — | 1 | — | — | 1 |
| Therapeutics | D013812 | — | — | — | — | 1 | — | — | 1 |
| Chikungunya virus | D002646 | — | — | — | — | 1 | — | — | 1 |
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | — | 1 | — | — | 1 |
| Recurrence | D012008 | — | — | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Respiratory distress syndrome | D012128 | EFO_1000637 | J80 | — | 2 | — | — | 2 | 4 |
| Viral pneumonia | D011024 | EFO_0007541 | J12.9 | — | 2 | — | — | — | 2 |
| Neoplasms | D009369 | — | C80 | 1 | 1 | — | — | — | 2 |
| Systemic lupus erythematosus | D008180 | HP_0002725 | M32 | — | 2 | — | — | — | 2 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 2 | — | — | — | 2 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | — | 1 | — | — | 1 | 2 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | 1 | — | — | 1 | 2 |
| Prediabetic state | D011236 | EFO_1001121 | R73.03 | — | 1 | — | — | 1 | 2 |
| Dyslipidemias | D050171 | HP_0003119 | — | — | 1 | — | — | 1 | 2 |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | — | 1 | — | — | 1 | 2 |
Show 19 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pharmacokinetics | D010599 | — | — | 1 | — | — | — | 1 | 2 |
| Small cell lung carcinoma | D055752 | — | — | 2 | — | — | — | — | 2 |
| Gliosarcoma | D018316 | — | — | 1 | — | — | — | — | 1 |
| Headache | D006261 | HP_0002315 | R51 | 1 | — | — | — | — | 1 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | — | — | — | — | 1 |
| Tuberculosis | D014376 | EFO_0000774 | A15-A19 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Acute kidney injury | D058186 | HP_0001919 | N17 | — | — | — | — | 1 | 1 |
| Iatrogenic disease | D007049 | — | — | — | — | — | — | 1 | 1 |
| Respiratory insufficiency | D012131 | HP_0002093 | J96.9 | — | — | — | — | 1 | 1 |
| Psoriatic arthritis | D015535 | EFO_0003778 | L40.5 | — | — | — | — | 1 | 1 |
| Disease resistance | D060467 | — | — | — | — | — | — | 1 | 1 |
| Prolactinoma | D015175 | HP_0006767 | — | — | — | — | — | 1 | 1 |
| Macular degeneration | D008268 | EFO_0001365 | H35.30 | — | — | — | — | 1 | 1 |
| Respiratory tract infections | D012141 | — | J06.9 | — | — | — | — | 1 | 1 |
| Neonatal sepsis | D000071074 | HP_0040187 | — | — | — | — | — | 1 | 1 |
| Diarrhea | D003967 | HP_0002014 | R19.7 | — | — | — | — | 1 | 1 |
Show 4 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Chloroquine |
| INN | chloroquine |
| Description | Chloroquine is an aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis. It has a role as an antimalarial, an antirheumatic drug, a dermatologic drug, an autophagy inhibitor and an anticoronaviral agent. It is an aminoquinoline, a secondary amino compound, a tertiary amino compound and an organochlorine compound. It is a conjugate base of a chloroquine(2+). |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCN(CC)CCCC(C)Nc1ccnc2cc(Cl)ccc12 |
Identifiers
| PDB | — |
| CAS-ID | 54-05-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL76 |
| ChEBI ID | 3638 |
| PubChem CID | 2719 |
| DrugBank | DB00608 |
| UNII ID | 886U3H6UFF (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
PSAP
PSAP
Organism
Homo sapiens
Gene name
PSAP
Gene synonyms
GLBA, SAP1
NCBI Gene ID
Protein name
prosaposin
Protein synonyms
precursor of saposins, Proactivator polypeptide, saposin-A, saposin-B, saposin-C, saposin-D, sphingolipid activator protein-1, sphingolipid activator protein-2
Uniprot ID
Mouse ortholog
Psap (19156)
prosaposin (Q61207)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Chloroquine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 64,963 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
50,140 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use